insight
✂️ 성형 🏥 중증 탈모 한방 반려 게놈 🏥 강남차 🌐 전체
← 뒤로

Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study.

🟢 신뢰도 높음 · RCT (무작위 임상시험) 🧑 쉬운 모드
💡 한 문장 핵심

양성 전립선비대증에 대한 finasteride 치료의 효능과 안전성: 2년 무작위 대조 시험 결과 (PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study.

🦱 탈모 🔵 RCT
무작위 임상시험 4/5 보강
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 📖 저널 OA 100% 2021: 4/4 OA 2022: 3/3 OA 2023: 4/4 OA 2024: 3/3 OA 2025: 5/5 OA 2026: 10/10 OA 2021~2026 1996 Vol.155(9) p. 1251-9 피인용 17회 참고 13건 cited 226 OA RCR 7.25 Urinary Bladder and Prostate Researc
TL;DR Finasteride is a well-tolerated and effective alternative to watchful waiting in the treatment of moderate BPH and the incidence of adverse events related to sexual dysfunction were significantly higher in the finasteride group than in the placebo group.
출처
PubMed PMC OpenAlex Semantic 마지막 보강 2026-05-12
📑 코퍼스 인용 관계 · 인용됨 17 · 인용함 13
→ 이 논문이 인용한 논문 (4) ▾
📑 인용한 논문 (6) ▾
연도별 인용 (2012–2024) · 합계 88
OpenAlex 토픽 · Urinary Bladder and Prostate Research Prostate Cancer Diagnosis and Treatment Pelvic floor disorders treatments

Nickel JC, Fradet Y, Boake RC, Pommerville PJ, Perreault JP, Afridi SK

📖 무료 전문 🟢 PMC 전문 PMC1335066 🔓 OA PDF oa
PubMed ↗ BibTeX ↓ RIS ↓

Abstract

[OBJECTIVE] To evaluate the efficacy and safety of 2 years' treatment of moderate benign prostatic hyperplasia (BPH) with finasteride.

[DESIGN] Double-blind, parallel-group, placebo-controlled, multicentre, prospective randomized study.

[SETTING] Outpatient care in 28 centres across Canada.

[PARTICIPANTS] Men aged 45 to 80, in good health, with moderate BPH and no evidence of prostate cancer. A total of 613 men were entered into the study; 472 completed the 2 years of treatment.

[INTERVENTION] After 1 month of receiving a placebo (run-in period), patients were given either finasteride (5 mg/d) or a placebo for 2 years.

[EFFICACY] changes from baseline in BPH symptom scores, maximum urinary flow rates and prostate volume.

[SAFETY] onset, course and resolution of all adverse events during the treatment period.

[RESULTS] In the efficacy analyses the mean BPH symptom scores decreased 2.1 points (from 15.8 to 13.7) in the finasteride group, as compared with a decrease of 0.7 points (from 16.6 to 15.9) in the placebo group (P < or = 0.01). The maximum urinary flow rate increased by a mean of 1.4 mL/s (from 11.1 to 12.5 mL/s) in the finasteride group, as compared with an increase of 0.3 mL/s (from 10.9 to 11.2 mL/s) in the placebo group (p < or = 0.01). The mean prostate volume decreased by 21% (from a mean volume of 44.1 cm3 at baseline) in the treatment group; it increased by 8.4% (from a mean volume of 45.8 cm3 at baseline) in the placebo group (p < or = 0.01). In the safety analysis, the proportion of patients who experienced any adverse event was similar in the two groups (81.0% in the treatment group and 81.2% in the placebo group). However, the incidence of adverse events related to sexual dysfunction were significantly higher in the finasteride group than in the placebo group (ejaculation disorder 7.7% v. 1.7% and impotence 15.8% v. 6.3%; p < or = 0.01 for both parameters).

[CONCLUSION] Finasteride is a well-tolerated and effective alternative to watchful waiting in the treatment of moderate BPH.
🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • OR 0.01
📝 환자 설명용 한 줄

Finasteride is a well-tolerated and effective alternative to watchful waiting in the treatment of moderate BPH and the incidence of adverse events related to sexual dysfunction were significantly high

이 논문을 인용하기

↓ .bib ↓ .ris
APA 7 Nickel, J. C., Fradet, Y., Boake, R. C., Pommerville, P. J., Perreault, J. P., Afridi, S. K., & Elhilali, M. M. (1996). Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: Results of a 2-year randomized controlled trial (the prospect study). Proscar safety plus efficacy canadian two year study.. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 155(9), 1251-9.
Vancouver Nickel JC, Fradet Y, Boake RC, Pommerville PJ, Perreault JP, Afridi SK, et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. CMAJ : Cana. Medi. Asso. jour. = jour. de l'As. medi. cana.. 1996;155(9):1251-9.
AMA 11 Nickel JC, Fradet Y, Boake RC, Pommerville PJ, Perreault JP, Afridi SK, et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. CMAJ : Cana. Medi. Asso. jour. = jour. de l'As. medi. cana.. 1996;155(9):1251-9.
Chicago Nickel, J. C., Fradet, Y., Boake, R. C., Pommerville, P. J., Perreault, J. P., Afridi, S. K., and Elhilali, M. M.. 1996. "Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study." CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 155 (9): 1251-9.
MLA 9 Nickel, J. C., et al. "Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study." CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, vol. 155, no. 9, 1996, pp. 1251-9.
PMID 8911291 ↗

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

인용 관계

그래프 OA 노드: 7/12 (58%) · 참조 1편 · 후속 6편

이 논문이 참조한 문헌 13

외부 PMID 9건 (DB 미수집)

이 논문을 인용한 후속 연구 17

같은 제1저자의 인용 많은 논문 (5)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🟢 PMC 전문 열기